Luca A Fumagalli - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Luca A Fumagalli

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006

Immunotherapy and prognostic factorsLuca A Fumagalli, Fernando Brivio

Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2003

Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapyLuca A Fumagalli, Jan Vinke, Wilco Hoff, et al.

Anticancer Research|December 6, 2015

Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast CancerFrancesco Recchia, Giampiero Candeloro, Michele Rosselli, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006

Immunotherapy and prognostic factorsLuca A Fumagalli, Fernando Brivio

Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2003

Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapyLuca A Fumagalli, Jan Vinke, Wilco Hoff, et al.

Anticancer Research|December 6, 2015

Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast CancerFrancesco Recchia, Giampiero Candeloro, Michele Rosselli, et al.

Pageof 1